Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (ATYR)
NASDAQ:ATYR
ATYR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.58 - $5.98
Previous CloseN/A
Volume346.43K
Average Volume (3M)3.42M
Market Cap
$519.79M
Enterprise Value$503.72M
Total Cash (Recent Filing)$76.35M
Total Debt (Recent Filing)$12.99M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 13, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding89,004,430
10 Day Avg. Volume3,053,777
30 Day Avg. Volume3,418,234
Financial Highlights & Ratios
PEG Ratio-1.12
Price to Book (P/B)6.38
Price to Sales (P/S)0.00
P/FCF Ratio-7.92
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue476.11
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$22.33Price Target Upside285.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
aTyr Pharma News
Bulls Say, Bears Say
Bulls Say
Investor ConfidenceAchieving significant steroid reduction and positive quality of life benefits should improve investor confidence on payer access and adoption.
Market PotentialEfzofitimod could be a $2B+ drug in pulmonary sarcoidosis if results are positive.
Trial DesignThe study is optimized for success via a favorable steroid tapering trial design and strong study execution by ATYR.
Bears Say
Data UncertaintyThe company did not specify which dose was used in the patients, making it difficult to compare results to the placebo arm.
Market RiskIf efzofitimod's Phase 3 trial fails, the company has no other late-stage assets and limited cash, thus it could trade down to a ~$50MM market cap.
Trial Duration ConcernsThe key unknown is how these patients will behave in the 24-48 weeks — whether they can maintain the regimen/co-treatment at 24 weeks through 48 weeks.
Options Prices
Currently, No data available
---
Ownership Overview
1.56% Insiders
30.64% Mutual Funds
<0.01% Other Institutional Investors
58.40% Public Companies and Individual Investors
ATYR FAQ
What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was $1.58 and its highest was $5.98 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is $519.79M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s upcoming earnings report date is Aug 13, 2025 which is in 25 days.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on May 07, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.191 by $0.021.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -0.19.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 89,004,430 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.191. Following the earnings report the stock price went up 5.696%.
Which hedge fund is a major shareholder of aTyr Pharma?
Currently, no hedge funds are holding shares in ATYR
aTyr Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.33 (285.66% Upside)
$22.33 (285.66% Upside)
Blogger Sentiment
Bullish
ATYR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
242.60%
12-Months-Change
Fundamentals
Return on Equity
-79.51%
Trailing 12-Months
Asset Growth
-14.13%
Trailing 12-Months
Company Description
aTyr Pharma
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
ATYR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Read More>ATYR Stock 12 Month Forecast
Average Price Target
$22.33
▲(285.66%Upside)
Technical Analysis
Arcturus Therapeutics
―
Olema Pharmaceuticals
―
ATAI Life Sciences
―
Monte Rosa Therapeutics
―
Aura Biosciences Inc
―